Disseminated intravascular coagulation future or investigational therapies

Disseminated intravascular coagulation Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Disseminated intravascular coagulation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Disseminated intravascular coagulation future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Disseminated intravascular coagulation future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Disseminated intravascular coagulation future or investigational therapies
CDC on Disseminated intravascular coagulation future or investigational therapies
Disseminated intravascular coagulation future or investigational therapies in the news
Blogs on Disseminated intravascular coagulation future or investigational therapies
Directions to Hospitals Treating Disseminated intravascular coagulation
Risk calculators and risk factors for Disseminated intravascular coagulation future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

• Phase I trials suggest that infusion of activated protein C may also benefit patients with DIC.

  • The theory is that APC normally inactivates Va and VIIIa, resulting in a decrease in thrombin formation, and promotes fibrinolysis by inactivating plasminogen activator inhibitor.

• Tissue factor pathway inhibitor has been shown to decrease mortality in baboon models of DIC with E. coli septic shock.
• Agents such as ASA (aspirin), ticlopidine, dextran and GP IIb/IIIa inhibitors are also being examined with the goal of reducing platelet activation.
• Currently, if fibrinolysis and hemorrhage appears to be more of a problem than clotting, the only options are antifibrinolytic agents, such as tranexamic acid. However, the risks of microvascular clot formation have limited its use.